CBD is a chemical component derived from hemp and it is well-known for its therapeutic qualities. It is increasingly being used to treat a variety of medical ailments, such as pain alleviation, anxiety, dystonia, Crohn's disease, Parkinson's disease, and others. As a result, CBD is gaining popularity in many different parts of the world. CBD's adaptability is shown in its numerous forms, which include capsules, patches, oils, extracts, vape pens, and topical skin treatments.

CBD's popularity is increasing in response to the growing demand for health and wellness solutions. CBD-based products are gaining popularity among both consumers and traditional merchants due to their numerous health benefits. Furthermore, the increasing number of regulatory approvals is a crucial driver of market growth.

Cannabis research has increased in recent years as more jurisdictions across the world have legalized medical marijuana usage. The expansion of legal access has resulted in a rise in scientific curiosity, with academicians eager to investigate cannabis's possible uses and effects.

This article examines the most recent and promising cannabis research trends, ranging from improved farming practices to new delivery systems for cannabis products or cannabis-based treatments.


Delta-8 and other cannabinoids in cannabis products are on the rise. If present cannabis trends continue, it appears that minor cannabinoids such as CBD and Delta-8 will experience a surge in 2023. CBD is a non-psychoactive cannabinoid that may offer health benefits without making you high. CBD derived from hemp that has less than 0.3% THC is lawful to be consumed and sold in India. Delta-8 is a kind of THC that produces a more modest high. Delta-8 has also gained popularity.

Many stores already sell CBD-only products or THC-containing CBD goods from where you can buy cbd products. Extending your product line and producing new products containing different cannabinoids could be a major cannabis trend in 2023.

Cannabis produces more than 120 additional cannabinoids in addition to the primary phytocannabinoids THC and CBD. Minor (or rare) cannabinoids are phytocannabinoids found in small concentrations in the cannabis plant, such as cannabinol (a derivative of THC) and cannabigerol (the precursor to CBD).

Minor cannabinoids have not received as much attention as CBD or THC. Nonetheless, recent research has revealed potential therapeutic benefits for neuropathic pain, neurological illnesses, epilepsy, cancer, and skin disorders.

The preliminary research findings are encouraging, but much of our present understanding of the medical effects of minor cannabinoids is based on tiny studies rather than thorough clinical trials. Despite the popularity of cannabis products, many claims about their efficacy still need to be shown in large clinical trials. Knowing their mechanism of action and how minor cannabinoids interact with other medications is also important before claiming their therapeutic properties.

The global CBD (Cannabidiol) market is expanding rapidly, with an estimated value of $6.17 billion by 2023. During the forecast period, this astonishing leap is expected to occur at an astounding compound annual growth rate (CAGR) of 27%.


In line with this trend, the National Centre for Complementary and Integrative Health (NCCIH) issued a Notice of Special Interest with the goal of encouraging mechanistic study into the therapeutic advantages of minor cannabinoids and terpenes in cannabis. As researchers learn more about the cannabis plant and its constituents, we will certainly gain a greater knowledge of the health benefits of lesser cannabinoids and how they might be used in the pharmaceutical business.